This GHK-Cu Canada information page summarizes the copper-peptide complex’s chemical identity, investigational research status, evidence limitations and Canadian regulatory context.
What is GHK-Cu?
GHK-Cu is a coordination complex formed when the tripeptide glycyl-L-histidyl-L-lysine, abbreviated GHK, binds a copper ion. It is also known as copper tripeptide-1 or prezatide copper. GHK-Cu is chemically distinct from the uncomplexed GHK peptide.
The complex is identified by CAS number 89030-95-5. A commonly used neutral formula representation is C14H22CuN6O4, with a molecular weight of approximately 401.91 g/mol. PubChem represents the charged species as C14H23CuN6O4+ with a molecular weight of 402.92 g/mol under CID 71587328. These differences reflect protonation and charge representation; researchers should compare the batch-specific analytical documentation with the stated reference form.
GHK-Cu Canada: regulatory status
GHK-Cu is not authorized by Health Canada as an injectable drug for human or veterinary use. Health Canada specifically identifies GHK-Cu among unauthorized injectable peptide drugs and has also reported a Canadian recall involving unauthorized GHK-Cu active pharmaceutical ingredient powder.
This material is presented strictly for legitimate laboratory and analytical research. It is not a medication, natural health product, veterinary product or substitute for professional healthcare. It is not for human or animal consumption, administration, injection, therapeutic use or diagnostic use. “Research use only” labelling does not itself provide an exemption from Canadian regulatory requirements.
Research information
- Name: GHK-Cu
- Synonyms: copper tripeptide-1; prezatide copper
- Peptide sequence: Gly-His-Lys complexed with copper
- Displayed amount: 200 mg
- Neutral formula representation: C14H22CuN6O4
- Approximate molecular weight: 401.91 g/mol for the neutral representation
- CAS number: 89030-95-5
- PubChem CID: 71587328
- Research status in Canada: investigational and unauthorized for injectable human or veterinary use
Evidence and research limitations
Published GHK-Cu literature includes laboratory studies involving peptide coordination chemistry, cell cultures and other experimental models. Findings from in-vitro or animal research cannot establish safety or effectiveness in humans or animals. This page does not present or imply cosmetic, anti-aging, healing or other therapeutic benefits, and it provides no dosage, route of administration or treatment protocol.
Researchers should confirm complex identity, copper content, peptide content, counterions, water content and analytical method using batch-specific documentation. Chemical identity or chromatographic purity does not establish sterility, clinical safety, effectiveness or authorization for use as a health product.
References
Regulatory Notice:
This product has not been evaluated by the Food and Drug Administration (FDA). It is not approved for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease.
Important Research Note:
The information provided on this website is for research and educational purposes only. This information does not constitute medical advice, diagnosis, or treatment. Consult with qualified healthcare professionals for medical guidance.
